The ECM-CART project aims to demonstrate that the targeted delivery of nano-formulated exogenous antigens to the extracellular matrix (ECM) of brain tumors provides a safe and specific target for chimeric antigen receptor T-cells (CAR-T) for the treatment of glioblastoma.
This project is an original approach for the treatment of glioblastoma using nanomedicine-actuated CAR-T therapy, granted within the EuroNanomed III Joint Transnational Call 2021. The international consortium is comprised by public health organisms Health Research Institute of Santiago de Compostela (IDIS) and Tel Aviv Sourasky Medical Center, academic groups from the University of Tartu and Tel Aviv University, and the SME GalChimia. The total budget for the project is €1,2M.
To carry out this project, GalChimia is receiving national funding from the Spanish Ministry of Science and Innovation through the Centre for the Development of Industrial Technology (CDTI).
